End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.47 CNY | -0.63% | +7.37% | -15.97% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 28.7 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.97% | 269M | - | ||
+14.65% | 64.32B | A- | ||
-3.80% | 45.95B | A- | ||
+13.69% | 39.61B | B+ | ||
+20.84% | 25.74B | A- | ||
+8.66% | 18.75B | C+ | ||
+1.27% | 17.23B | B+ | ||
-21.03% | 15.86B | A- | ||
+0.81% | 15.03B | B+ | ||
-12.70% | 13.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300610 Stock
- Ratings Yangzhou Chenhua New Material Co., Ltd.